LIDCO GROUP PLC 
By ("LiDCO" or the "Company")
Result of AGM
LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, announces that all resolutions proposed at the Company's Annual General Meeting held today at 11am at the offices of Abchurch Communications, 125 Old Broad Street, London EC2N 1AR, were duly passed.
- Ends -
For further information, please contact:
LiDCO Group Plc | |
Terry O'Brien (CEO) |
Tel: +44 (0)20 7749 1500 |
Paul Clifford (Finance Director) | |
John Rowland (Company Secretary) |
FinnCap | |
| Geoff Nash / Henrik Persson Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 |
Media enquiries:
Abchurch | |
Sarah Hollins / Adam Michael / Joanne Shears /
Jamie Hooper |
Tel: +44 (0) 20 7398 7719 |
Jamie.hooper@abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:
· |
Early and rapid warning of change |
· |
Clear indication of therapeutic route: fluid or
drug |
· |
Quantification of hemodynamic response,
particularly stroke volume |
· |
Permits more effective delivery of fluids - the
right amount at the right time |
· | Advanced hemodynamic care has been shown to
contribute to: - Reduced morbidity and complications, length of
stay & overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
* LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
|
distributed by
|
